Ramsay Health Care’s proposed separation of its 52.79% Ramsay Santé stake has reached a key regulatory milestone, with ASIC registering the Demerger Booklet. Shareholders will vote on the transaction on 24 November, but approval remains only one step in a process that could create two separately traded healthcare exposures.
- ASIC registers Ramsay Santé Demerger Booklet
- Shareholders to vote on 24 November 2026
- Eligible holders expected to receive 0.25 Santé security per Ramsay share
- ASX CDI listing remains subject to approval
- Demerger costs estimated at A$59 million before tax
ASIC registration puts the demerger before shareholders
Ramsay Health Care Limited (ASX:RHC) has cleared the next formal hurdle in its proposed demerger of Ramsay Santé, after ASIC registered the Demerger Booklet. The document sets out the proposed distribution of Ramsay Group’s entire 52.79% holding in the European healthcare operator to eligible Ramsay shareholders.
The registration follows the first court order for the demerger vote, which allowed Ramsay to convene the shareholder meetings. The General Meeting and Scheme Meeting are scheduled to follow Ramsay’s annual general meeting on 24 November 2026. The scheme requires more than 50% of shareholders voting by number and at least 75% of votes cast, while the capital reduction requires a simple majority.
Shareholders would receive a direct European healthcare interest
If approved and implemented, eligible shareholders would retain their existing Ramsay shares and receive 0.25 Ramsay Santé security for every Ramsay share held on the 2 December record date, rounded down to the nearest whole security. Ramsay expects those securities to be issued as ASX-traded CHESS Depositary Interests, or CDIs, provided Ramsay Santé secures its Foreign Exempt Listing and quotation approval. Otherwise, shareholders may receive Ramsay Santé shares traded on Euronext Paris in euros.
The proposed separation would turn what is currently an indirect controlling exposure into a direct, non-controlling interest. Ramsay says the structure would simplify its financial reporting, allow management to focus on its Australian and UK operations, and give investors more flexibility over their exposure to the two businesses. The booklet also makes clear that Ramsay’s five nominated directors are expected to leave the Ramsay Santé board, which is intended to have a majority of independent directors after implementation.
The numbers show two very different businesses
The proposed post-demerger Ramsay reported A$9.4 billion of pro forma revenue, A$806.8 million of EBIT and A$386.6 million of net profit after tax for FY2026. Its remaining portfolio would comprise the Australian private hospital business, Ramsay UK and Elysium Healthcare. Ramsay Australia delivered A$6.81 billion of revenue and A$629.9 million of EBIT in FY2026, while the UK hospital and mental health operations contributed A$159.0 million and A$17.9 million of EBIT respectively.
Ramsay Santé generated A$9.28 billion of revenue and A$298.6 million of EBIT in FY2026, but recorded a net loss after tax of A$65.2 million on the historical figures presented in the booklet. Its €1.75 billion senior debt facilities were refinanced in July 2026 with maturities extended to 2033. That refinancing gives the European business a standalone funding structure, but it does not erase its exposure to government tariffs, wage costs, public contracts and relatively high leverage.
Costs, liquidity and post-listing selling pressure remain risks
The transaction is estimated to cost about A$59 million before tax, comprising approximately A$40 million of transaction costs and A$19 million of implementation costs. Around A$27 million is expected to be incurred regardless of whether shareholders approve the separation. Ramsay’s independent expert, Deloitte Corporate Finance, concluded that the advantages outweigh the disadvantages in the absence of a superior proposal, while noting the smaller post-demerger Ramsay would be less diversified.
The booklet also flags uncertainty around the combined market value of Ramsay and Ramsay Santé after separation. CDI holders would face AUD/EUR currency exposure and may not see an active or liquid ASX market develop. Some institutional shareholders may be unable or unwilling to retain a European healthcare security, potentially creating selling pressure when the CDIs begin trading. Small shareholders holding 500 Ramsay shares or fewer would default to cash through the sale facility unless they elect to receive securities.
Court approval and CDI quotation are the next gates
The demerger still depends on the shareholder votes, regulatory approvals, ASX quotation of the CDIs if that route is chosen, and approval by the Supreme Court of New South Wales. The second court hearing is expected on 27 November, with the scheme expected to become effective on 30 November if the conditions are satisfied. Implementation is scheduled for 9 December, although dates after the shareholder meetings remain indicative.
The immediate question is therefore procedural, but the eventual test will be commercial: whether a more transparent Ramsay can convert its Australian and UK focus into stronger returns, while Ramsay Santé uses a much broader shareholder base to improve liquidity and address the funding and margin pressures that have kept it loss-making at the bottom line.
Bottom Line?
ASIC registration moves Ramsay’s separation from proposal to shareholder decision, but the more consequential test will begin after the vote: price discovery, liquidity and execution as two distinct companies.
Questions in the middle?
- Will Ramsay Santé CDIs receive ASX quotation, or will some shareholders need to trade directly through Euronext Paris?
- How much short-term selling pressure could arise from institutional holders unable to retain a European healthcare exposure?
- Can Ramsay Santé improve margins and eventually return to profitability while operating under regulated tariffs and elevated debt?